ChemoCentryx, Inc.

NasdaqGS:CCXI Voorraadrapport

Marktkapitalisatie: US$3.7b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

n/a

Dividendrendement

-0.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement-0.2%
Toekomstig dividendrendementn/a
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente updates van dividend en inkoop

Geen updates

Recent updates

Seeking Alpha • Oct 18

ChemoCentryx shareholders approve $4.7B merger with Amgen

ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company. With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels. NASDAQ said ChemoCentryx's (NASDAQ:CCXI) anticipated last day of trading will be Oct. 19.
Seeking Alpha • Aug 09

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

ChemoCentryx press release (NASDAQ:CCXI): Q2 GAAP EPS of -$0.44 misses by $0.03. Revenue of $11.76M (+553.3% Y/Y) misses by $9.89M. On August 3, 2022, the company entered into merger deal with Amgen under which Amgen will acquire the Company for $52.00 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction is subject to the company's stockholder approval, regulatory approvals and other customary closing conditions, and is expected to close in the fourth quarter of 2022. Also Read: Amgen posts 2Q beat, trims earnings guidance; new drugs outperform
Seeking Alpha • Jun 21

ChemoCentryx: Revisiting The Investment Case

Today, we revisit a biopharma concern called ChemoCentryx for the first time since late in 2021. The company is in the initial rollout of its primary product TAVNEOS, which is approved for one indication and in development for three other diseases. ChemoCentryx has a solid balance sheet and analyst firms are modeling explosive revenue growth ahead for the company. An investment analysis follows in the paragraphs below.
Analyseartikel • Jun 06

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 03

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

CCXI got its first approval last October. Revenue and patient uptake has been good. A few more quarters will be needed to assess the company properly.
Analyseartikel • Feb 11

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyseartikel • Jan 21

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Celebrations may be in order for ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders, with the analysts delivering a...
Seeking Alpha • Dec 15

Checking In On ChemoCentryx

Today, we put mid-cap biopharma name ChemoCentryx in the spotlight. The company's primary compound was recently approved for the treatment of vasculitis. A full investment analysis is presented in the paragraphs below.
Analyseartikel • Oct 09

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Sep 29

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx is developing Avacopan - a C5 complement receptor inhibitor - for several autoimmune conditions. The company has an upcoming PDUFA date for Avacopan in ANCA vasculitis - the FDA will make its decision on whether to approve the drug on October 7th. The original date was July 2021 but the decision was delayed after ChemoCentryx provided additional data. An FDA Adcom was split over an approval verdict in May. ChemoCentryx stock traded at $68 prior to the Adcom and PDUFA date delay, based on a $1.9bn peak sales potential. Today, shares trade at $20. Avacopan won approval in Japan this week - an encouraging sign - but I suspect the FDA may reject the therapy this time around, and that ChemoCentryx market valuation will fall further as a result - it will be a marginal decision.
Seeking Alpha • Aug 24

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021. Regulatory review is ongoing with the PDUFA extended to Oct. 6, 2021, in response to new filing by CCXI which the FDA designated as a major amendment to the NDA. The good news is that CCXI has not been issued the dreaded complete response letter. The outcome of the PDUFA is dependent on a satisfactory rebuttal to the Adcom questions and comments. Read on for details on the potential regulatory review outcome.
Analyseartikel • Aug 11

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

The latest analyst coverage could presage a bad day for ChemoCentryx, Inc. ( NASDAQ:CCXI ), with the analysts making...
Seeking Alpha • Jul 25

ChemoCentryx: CRL Less Likely

In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date. There are reasons to think the outcome may be positive.
Analyseartikel • Jul 11

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Today we will run through one way of estimating the intrinsic value of ChemoCentryx, Inc. ( NASDAQ:CCXI ) by estimating...
Analyseartikel • Jun 15

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Mar 03

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

We feel now is a pretty good time to analyse ChemoCentryx, Inc.'s ( NASDAQ:CCXI ) business as it appears the company...
Analyseartikel • Feb 04

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Dec 31

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Some ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders may be a little concerned to see that the Independent Director...
Analyseartikel • Dec 23

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Today is shaping up negative for ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders, with the analysts delivering a...
Analyseartikel • Dec 13

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
Analyseartikel • Nov 22

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

In this article we are going to estimate the intrinsic value of ChemoCentryx, Inc. (NASDAQ:CCXI) by taking the...

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van CCXI in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van CCXI zijn gestegen.

Dividendrendement versus markt

ChemoCentryx Dividendrendement versus markt
Hoe verhoudt CCXI dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (CCXI)n/a
Markt onderkant 25% (US)1.4%
Markt Top 25% (US)4.3%
Gemiddelde industrie (Biotechs)2.4%
Analist prognose (CCXI) (tot 3 jaar)n/a

Opmerkelijk dividend: Het dividendrendement van CCXI kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van CCXI kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio CCXI te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat CCXI geen uitbetalingen heeft gerapporteerd.

Ontdek bedrijven met een sterk dividend

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2022/10/23 21:59
Aandelenkoers aan het einde van de dag2022/10/19 00:00
Inkomsten2022/06/30
Jaarlijkse inkomsten2021/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

ChemoCentryx, Inc. wordt gevolgd door 15 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Madhu KumarB. Riley Securities, Inc.
Harshita PolishettyB. Riley Securities, Inc.
Dae Gon HaBTIG